104 related articles for article (PubMed ID: 9729018)
1. Sorting the hype from the facts in melanoma.
Autier P; Boyle P; Doré JF
Lancet; 1998 Aug; 352(9129):738-9. PubMed ID: 9729018
[No Abstract] [Full Text] [Related]
2. Adjuvant therapy of melanoma.
Retsas S
Lancet; 1998 Aug; 352(9129):737-8. PubMed ID: 9729017
[No Abstract] [Full Text] [Related]
3. Adjuvant interferon in the treatment of melanoma.
Middleton MR
Br J Cancer; 1999 Aug; 80(11):1679-80. PubMed ID: 10468281
[No Abstract] [Full Text] [Related]
4. Adjuvant interferon alfa-2b for high-risk melanoma.
Retsas S
J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
[No Abstract] [Full Text] [Related]
5. Adjuvant IFN alpha2 therapy of melanoma.
Kirkwood JM
Lancet; 1998 Jun; 351(9120):1901-3. PubMed ID: 9654253
[No Abstract] [Full Text] [Related]
6. Clinical prognostic factors in adjuvant melanoma trial.
Nathanson L
J Clin Oncol; 1996 Jun; 14(6):1967-8. PubMed ID: 8656271
[No Abstract] [Full Text] [Related]
7. Interferon adjuvant therapy of melanoma.
Kirkwood JM; Wazer D; Rosenstein M
Cancer; 1997 May; 79(9):1843-6. PubMed ID: 9129006
[No Abstract] [Full Text] [Related]
8. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
Johnson DM; Hayat SQ; Burton GV
J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
[No Abstract] [Full Text] [Related]
9. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?].
Saiag P
Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432
[No Abstract] [Full Text] [Related]
10. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
Lohmann CP; Kroher G; Bogenrieder T; Spiegel D; Preuner J
Lancet; 1999 Apr; 353(9161):1326. PubMed ID: 10218534
[No Abstract] [Full Text] [Related]
11. A case of animal-type melanoma (or pigmented epithelioid melanocytoma?): an open prognosis.
Vezzoni GM; Martini L; Ricci C
Dermatol Surg; 2008 Jan; 34(1):105-9; discussion 110. PubMed ID: 18053035
[No Abstract] [Full Text] [Related]
12. Melanoma--part 2: management.
Thirlwell C; Nathan P
BMJ; 2008 Dec; 337():a2488. PubMed ID: 19047194
[No Abstract] [Full Text] [Related]
13. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa.
Mitchell MS; Darrah D; Stevenson L
Cancer Invest; 2002; 20(5-6):759-68. PubMed ID: 12197233
[No Abstract] [Full Text] [Related]
14. Recurrent laryngeal metastasis of a malignant melanoma: surgical therapy with the first application of mitomycin C.
Echternach M; Arndt S; Mattern D; Maier W; Richter B
J Otolaryngol Head Neck Surg; 2009 Feb; 38(1):E19-22. PubMed ID: 19344599
[No Abstract] [Full Text] [Related]
15. [Melanoma during pregnancy].
Pagès C; Misset JL; de Kerviler E; Bavoux F; Fernandez H; Viguier M
Ann Dermatol Venereol; 2012 Apr; 139(4):298-304; quiz 296-7, 306-7. PubMed ID: 22482486
[No Abstract] [Full Text] [Related]
16. [Role of interferon alfa-2 in melanoma. Results of a phase II study in 27 patients].
Bernengo MG; Doveil GC; Appino A; Sertoli MR; Ardizzoni A; Vidili MG
G Ital Dermatol Venereol; 1988 Apr; 123(4):185-8. PubMed ID: 3182009
[No Abstract] [Full Text] [Related]
17. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a.
Hanson DS; Leggette CT
Ann Pharmacother; 1997 Mar; 31(3):371-2. PubMed ID: 9066950
[No Abstract] [Full Text] [Related]
18. Adjuvant therapy of melanoma: at what cost?
Spitler LE
J Clin Oncol; 2001 Feb; 19(4):1226-8. PubMed ID: 11181688
[No Abstract] [Full Text] [Related]
19. Survival benefit in melanoma.
Williams MV; De Takats P; Parmar M
J Clin Oncol; 1997 May; 15(5):2172. PubMed ID: 9164233
[No Abstract] [Full Text] [Related]
20. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice.
Ravaud A; Bedane C; Geoffrois L; Lesimple T; Delaunay M
Br J Cancer; 1999 Aug; 80(11):1767-9. PubMed ID: 10468294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
